BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 5, 2012
View Archived Issues
Tragara multikinase inhibitor may be beneficial to treat triple-negative breast cancer
Read More
Phase II data presented on PEGylated therapy in previously treated metastatic breast cancer
Read More
Phase II results disclosed on PD-0332991
Read More
Dual ERK inhibitor shows promise as triple-negative breast cancer therapy
Read More
Two Cellceutix products expected to enter clinic this year
Read More
Phase II trial assesses proprietary Exelixis drug in metastatic breast cancer
Read More
New HCV NS5A inhibitors disclosed by Presidio Pharmaceuticals
Read More
Apricus Biosciences and Stellar Pharmaceuticals sign license agreement for MycoVa
Read More
Dosing completed in phase II trial of low-dose oral Proellex
Read More
Isotechnika licenses voclosporin to Vifor Pharma for certain regions
Read More
Euroscreen prepares new agents for diabetes and associated conditions
Read More
Novel inhibitors of cytochrome P450 enzymes synthesized by Angion Biomedica
Read More
Arrow Therapeutics claims novel HCV NS5B inhibitors
Read More
ACH-1625 receives FDA fast track status
Read More
Enanta Pharmaceuticals designs new compounds for hepatitis C virus infection
Read More
Quark Pharmaceuticals reports first-in-human data on siRNA drug candidate
Read More
Researchers at Albany Molecular Research patent novel GlyT-1 inhibitors
Read More
Cardiokine acquired by Cornerstone Therapeutics
Read More
Alkermes reports phase I/II ALKS-5461 study results
Read More
Alnylam reports preliminary results from phase I ALN-PCS trial
Read More
Alchemia treats first patient in pivotal phase III HA-irinotecan trial
Read More
Celldex begins phase II study of rindopepimut
Read More
PolyMedix completes enrollment in PMX-30063 study
Read More
Acacia Pharma begins phase II APD-421 trial
Read More
Biogen Idec and Isis enter collaboration on antisense drug for SMA
Read More